Published on 21/12/2025
How to Identify Red Flags in a Site’s Historical Trial Performance
Introduction: Why Red Flag Detection Is Essential in Feasibility
When selecting sites for a new clinical trial, evaluating historical performance is vital—but knowing what to avoid is just as important as identifying strengths. Red flags in a site’s past trial record can signal operational weaknesses, data integrity risks, or regulatory non-compliance. Ignoring these signals may lead to delays, deviations, or even sponsor audits.
Whether revealed through CTMS data, CRA notes, or inspection databases, these red flags must be incorporated into feasibility decisions. This article presents a detailed framework to identify and evaluate warning signs in a site’s trial history so sponsors and CROs can make informed, compliant, and risk-adjusted site selections.
1. Types of Red Flags in Site Historical Records
Red flags may emerge in different domains, and their severity should be considered based on context, recurrence, and mitigations:
- Enrollment issues: Underperformance or failure to meet targets without justification
- Deviation patterns: Repeated or serious protocol deviations across studies
- Regulatory findings: History of FDA 483s, Warning Letters, or MHRA/EMA inspection findings
- High screen failure or dropout rates: Suggests inadequate pre-screening or patient follow-up
- Audit trail irregularities: Missing records, backdating,
Any one of these may not disqualify a site alone, but when recurring or unaddressed, they signal deeper concerns.
2. Sources for Identifying Red Flags
A multifaceted review across data systems and documentation is required to uncover red flags. Key sources include:
- Clinical Trial Management System (CTMS): Past enrollment and deviation trends
- Monitoring Visit Reports: CRA observations and follow-up cycles
- Audit and QA systems: Internal audit findings, CAPA effectiveness records
- eTMF and Regulatory Docs: Delays in document submissions or missing logs
- Public databases: [FDA 483 Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/fda-inspection-database), [clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu), and other inspection records
Interviewing CRAs, project leads, and QA auditors involved in prior trials can also reveal undocumented concerns.
3. Red Flag Indicators by Trial Domain
Enrollment and Retention
- Enrolled <50% of target without documented reason
- High subject withdrawal/dropout (>20%)
- Misalignment between projected and actual enrollment timelines
Protocol Compliance
- >5 major deviations per 100 enrolled subjects
- Failure to report deviations within specified timelines
- Use of incorrect versions of ICF or CRFs
Data Quality
- Query resolution delays >7 days on average
- Inconsistencies between source data and CRF entries
- Backdating or unclear audit trails
Regulatory and Audit
- Previous FDA 483s for GCP violations
- Unresolved audit CAPAs or delayed CAPA closure
- Repeat findings across multiple audits
4. Case Study: Site Deselection Due to Deviation Pattern
During feasibility for a Phase II dermatology study, a site submitted strong infrastructure documentation and rapid IRB approval timelines. However, a review of historical records revealed the following in a prior study:
- 12 protocol deviations involving dosing errors
- 2 AE reporting delays beyond 7 days
- No documented CAPA for deviation recurrence
Despite strong feasibility responses, the sponsor excluded the site due to repeat non-compliance without evidence of learning or mitigation.
5. Sample Red Flag Evaluation Template
| Category | Red Flag | Severity | Justification Required |
|---|---|---|---|
| Enrollment | 50% target shortfall | Moderate | Yes |
| Deviations | 7 major deviations | High | Yes |
| Audit | FDA 483 for IP accountability | Critical | Mandatory CAPA |
| Staff | PI changed mid-study | Moderate | Yes |
This allows feasibility teams to apply consistent review criteria and document selection decisions clearly.
6. Regulatory Expectations and Risk-Based Selection
Per ICH E6(R2), sponsors must adopt a quality risk management approach in selecting investigators. Key regulatory expectations include:
- Site selection must consider previous compliance history
- Known high-risk sites should be justified or excluded
- Selection documentation must be retained in the TMF
- Risk-based monitoring plans should reflect past issues
Regulators may review site selection rationale during inspections, especially for previously audited sites.
7. How to Respond When Red Flags Are Identified
Red flags do not always mean automatic exclusion. Depending on the severity and recurrence, sponsors may:
- Request CAPA documentation and PI explanation
- Include site conditionally with enhanced monitoring
- Schedule an on-site qualification audit
- Delay selection pending sponsor QA review
- Exclude site but document rationale in CTMS/TMF
Final decisions should always be documented with objective evidence and cross-functional agreement.
8. SOPs and Feasibility Tools for Red Flag Management
Your organization should incorporate red flag assessments into SOPs and feasibility templates:
- Feasibility questionnaire section for prior audit findings
- CTMS fields for deviation, dropout, and CAPA metrics
- CRA comment boxes in site selection forms
- Standard scoring system for red flag severity
Such standardization ensures consistent and transparent risk evaluation across therapeutic areas and geographies.
Conclusion
Red flags in a clinical trial site’s historical record can signal potential threats to trial quality, timelines, and regulatory standing. By systematically identifying and evaluating these indicators—using data from audits, monitoring, CTMS, and regulatory sources—sponsors and CROs can make smarter feasibility decisions and build stronger quality oversight frameworks. In an era of risk-based GCP compliance, understanding red flags is no longer optional—it is essential for inspection readiness and trial success.